| 1. |
Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 Study. J Clin Oncol, 2019, 37(28): 2518-2527.
|
| 2. |
Kelly PJ, Weiss SE, Sher DJ, et al. Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. J Clin Oncol, 2010, 28(25): e433-e435.
|
| 3. |
Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol, 2017, 8: 561.
|
| 4. |
Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol, 2015, 33(31): 3541-3543.
|
| 5. |
Ricciuti B, Genova C, Bassanelli M, et al. Safety and efficacy of nivolumab in patients with advanced non-small-cell lung cancer treated beyond progression. Clin Lung Cancer, 2019, 20(3): 178-185.
|
| 6. |
Katz SI, Hammer M, Bagley SJ, et al. Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer. J Thorac Oncol, 2018, 13(7): 978-986.
|
| 7. |
Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy - a report of two cases. J Immunother Cancer, 2016, 4: 80.
|
| 8. |
Liu G, Chen T, Li R, et al. Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: a case report. Thorac Cancer, 2018, 9(9): 1190-1193.
|
| 9. |
Tseng YH, Ho HL, Lai CR, et al. PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion. J Thorac Oncol, 2018, 13(3): 447-453.
|
| 10. |
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol, 2017, 18(3): e143-e152.
|
| 11. |
Lee JH Long GV, Menzies AM, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol, 2018, 4(5): 717-721.
|
| 12. |
Cabel L, Proudhon C, Romano E, et al. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. Nat Rev Clin Oncol, 2018, 15(10): 639-650.
|
| 13. |
Dimitrakopoulou-Strauss A. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. Cancer Immunol Immunother, 2019, 68(5): 813-822.
|
1/5
WeChat